July 16, 2026
KT-621, an Oral STAT6 Degrader, Consistently Improves Moderate-to-Severe Atopic Dermatitis Across Body Regions: Phase 1b Results
American Academy of Dermatology (AAD) 2026 Innovation Academy
Atopic Dermatitis (AD)
Read More
June 12, 2026
KT-621, an Oral, Once Daily STAT6 Degrader: Pharmacokinetics, Pharmacodynamics, and Safety in Healthy Japanese Adults
Japanese Dermatological Association (JDA) 2026
Healthy Volunteers
Read More
May 15, 2026
Revolutionizing Immunology with Oral Medicines
American Thoracic Society (ATS) - Respiratory Innovation Summit 2026
Atopic Dermatitis (AD)
Asthma
Read More
May 15, 2026
KT-621 Treatment Induces Rapid STAT6 Degradation and Modulation of Th2 Gene Transcripts in Atopic Dermatitis Lesional Skin
Society for Investigative Dermatology (SID) 2026 – Late Breaking Presentation
Atopic Dermatitis (AD)
Read More
March 28, 2026
Clinical Activity and Safety of KT-621, an Oral STAT6 Degrader, in Moderate-to-Severe Atopic Dermatitis: Phase 1b Trial Results
American Academy of Dermatology (AAD) 2026 – Late Breaking Presentation
Atopic Dermatitis (AD)
Read More
September 29, 2025
Safety, Pharmacokinetics and Pharmacodynamics of KT-621, an Oral STAT6 Degrader, in Healthy Adults
European Respiratory Society (ERS) 2025 Congress – Late Breaking Presentation
Healthy Volunteers
Read More
September 17, 2025
The Potent and Selective Oral STAT6 Degrader, KT-621, Affects Gene Transcripts in Human Keratinocytes as Effectively as Dupilumab, and Blocks Th2 Inflammation in Atopic Dermatitis and Asthma Mouse Models
European Academy of Dermatology & Venereology (EADV) 2025
Atopic Dermatitis (AD)
Asthma
Read More
September 17, 2025
KT-621, an Oral, Once Daily, Targeted STAT6 Degrader: First-in-Human Phase 1a Safety, Pharmacokinetics, Pharmacodynamics and Th2 Biomarker Effects
European Academy of Dermatology & Venereology (EADV) 2025 – Late Breaking Presentation
Healthy Volunteers
Read More
May 19, 2025
Potent and Selective Oral STAT6 Degrader, KT-621, Inhibits IL-4 and IL-13 Functions in Human Cells and Blocks Th2 Inflammation in House Dust Mite Models of Asthma Prophylactically and Therapeutically
American Thoracic Society (ATS) 2025
Read More
May 17, 2025
Revolutionizing Immunology: Oral Medicines with Biologics-like Activity
American Thoracic Society (ATS) – Respiratory Innovation Summit 2025
Read More